Media January 10, 2025: MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease – Cancer Network MaaT PharmaJanuary 27, 2025
Media January 9, 2025: Microbiome trial boosts MaaT, sets path for EU marketing bid – The Pharma Letter MaaT PharmaJanuary 27, 2025
Media January 9, 2025: Maat Pharma Phase III microbiome trial hits endpoints as stock soars – Clinical Trials Arena MaaT PharmaJanuary 27, 2025
Media January 9, 2025: Microbiote: résultats positifs d’une étude clinique de MaaT Pharma – Agence France Presse (French Only) MaaT PharmaJanuary 27, 2025
Media January 9, 2025: MaaT Prepares For EMA Filing, US Expansion After Positive GVHD Readout – SCRIP MaaT PharmaJanuary 27, 2025
Media January 9, 2025: MaaT’s phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears – Fierce Biotech MaaT PharmaJanuary 27, 2025
Media January 9, 2025: La biotech lyonnaise MaaT Pharma prouve les vertus du microbiote – Les Echos (French Only) MaaT PharmaJanuary 27, 2025
Media January 9, 2025: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR – OncLive MaaT PharmaJanuary 27, 2025
Media January 8, 2025: MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment – Endpoints News MaaT PharmaJanuary 27, 2025
Media January 8, 2025: Drug From Bowel Bacteria Helps Blood Cancer Patients Facing Deadly Complication – Bloomberg MaaT PharmaJanuary 27, 2025
